Active, not recruitingPhase 2NCT05564403
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
Studying Perihilar cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ardaman ShergillAlliance for Clinical Trials in Oncology
- Intervention
- Binimetinib(drug)
- Enrollment
- 66 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Presbyterian Intercommunity Hospital, Whittier, California, United States
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
- UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05564403 on ClinicalTrials.govOther trials for Perihilar cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06986486Liver Transplantation for Unresectable Perihilar CholangiocarcinomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- RECRUITINGNANCT06850753En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant CriteriaOslo University Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT06717464Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract CancerTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNANCT06493734Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar CholangiocarcinomaErasmus Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT06178588Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic CholangiocarcinomaUniversity of Kansas Medical Center
- RECRUITINGNANCT06125769LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)Azienda Sanitaria Ospedaliera
- RECRUITINGPHASE4NCT05551299Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic TherapyUniversity of Leipzig
- RECRUITINGNANCT06964425Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot StudyUniversity Hospital Olomouc